01453nas a2200277   4500000000100000008004100001260001600042653002900058653002900087653002100116653001100137653001200148653001500160653002700175653001700202653001800219100001400237700001800251700001200269700001200281245010100293300001200394490000600406520074900412022001401161       1970                            d  c1970 Jan 2410aAnti-Inflammatory Agents10aClinical Trials as Topic10aErythema Nodosum10aHumans10aleprosy10aPhenazines10aPigmentation Disorders10aPrednisolone10aSerum Albumin1 aKarat A B1 aJeevaratnam A1 aKarat S1 aRao P S00aDouble-blind controlled clinical trial of clofazimine in reactive phases of lepromatous leprosy.  a198-2000 v13 a<p>A double-blind controlled trial in 24 lepromatous leprosy patients in reaction showed that clofazimine (Lamprene) controlled symptoms of erythema nodosum leprosum reaction in lepromatous leprosy better than prednisolone. Clofazimine also appeared to be significantly superior in preventing recurrence once the reaction had been controlled. There was a statistically significant rise in serum albumin among inpatients on clofazimine as compared with patients on prednisolone, but no difference in terms of neurological status, bacterial index, morphological index, and renal functions. Red/black hyperpigmentation was seen among practically all patients on clofazimine. No other side-effects or deleterious systemic effects were observed.</p>  a0007-1447